Research peptide head to head

Tesamorelin vs Sermorelin

Both are GHRH analogues. Sermorelin is the unmodified 29-amino-acid N-terminal fragment of human GHRH. Tesamorelin is a longer, stabilised 44-amino-acid analogue with an N-terminal modification that extends half-life. Tesamorelin is FDA-approved in the US (EGRIFTA, for HIV-associated lipodystrophy); Sermorelin (Geref) was discontinued. Neither has a UK marketing authorisation as a medicine.

AI-friendly summary · Tesamorelin vs Sermorelin

Tesamorelin and Sermorelin are both GHRH analogues. Sermorelin is the unmodified 29-amino-acid N-terminal fragment of human GHRH. Tesamorelin is a longer, stabilised 44-amino-acid analogue with an N-terminal modification that extends half-life. Tesamorelin is FDA-approved in the US as EGRIFTA for HIV-associated lipodystrophy, while Sermorelin (originally Geref) was discontinued. Neither holds a UK marketing authorisation, and both are sold research-use-only here. PeptideClear publishes no dosing or human-use protocols.

	Tesamorelin	Sermorelin
Class	GHRH analogue (stabilised)	GHRH analogue (unmodified)
Amino acids	44	29
Stability	N-terminal modification for half-life extension	Native GHRH fragment, short half-life
Regulatory status (US)	FDA-approved as EGRIFTA for HIV-associated lipodystrophy	Geref discontinued 2008
Regulatory status (UK)	No marketing authorisation; research use only	No marketing authorisation; research use only
Half-life	Approx 30 minutes (longer than Sermorelin)	10 to 20 minutes
Synthesis complexity	Higher (44-aa peptide)	Lower (29-aa)
Typical retail price	2 to 3x Sermorelin per equivalent quantity	Base GHRH analogue pricing

Cross-reference: Tesamorelin encyclopedia.

Frequently asked questions

What's the main difference between Tesamorelin and Sermorelin?

Both are GHRH (growth-hormone-releasing hormone) analogues. Sermorelin is the unmodified 29-amino-acid N-terminal fragment of human GHRH with a short half-life of 10 to 20 minutes. Tesamorelin is a longer stabilised 44-amino-acid analogue with N-terminal modification that extends half-life to roughly 30 minutes.

Which has a stronger regulatory record?

Tesamorelin is FDA-approved in the US (as EGRIFTA, for HIV-associated lipodystrophy) and remains in active circulation. Sermorelin was marketed as Geref by Serono but was discontinued in 2008. Neither holds a UK marketing authorisation as a medicine.

Are both legal in the UK?

Neither holds a UK marketing authorisation as a medicine. UK retailers sell both under "research use only, not for human or animal consumption" framing. Neither is a controlled drug under the Misuse of Drugs Act 1971.

Where can I buy Tesamorelin and Sermorelin in the UK?

Both are stocked by UK research peptide retailers including my-peptides, Pure Peptides UK, Direct Sarms, Aquila, Pinnacle, and Nooku. Tesamorelin tends to retail at 2 to 3 times Sermorelin per equivalent quantity because of the longer synthesis (44 vs 29 amino acids).

Which has more human RCT data?

Tesamorelin has the larger human evidence base, having gone through the full FDA approval pathway for HIV-associated lipodystrophy. Sermorelin has historical Geref trial data from its time on market. For non-approved indications, neither has current published phase III RCT data.

Ready to buy

Shop UK peptides, collagen and GLP-1 routes

Compare UK retailers, clinics and pharmacies across every PeptideClear category.

Shop UK products Find a UK clinic

Tesamorelin vs Sermorelin

Frequently asked questions

Shop UK peptides, collagen and GLP-1 routes

Related on PeptideClear

Legal and Registration

Standards and Governance

Domain Continuity